UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.43 Million Holdings in Artivion, Inc. $AORT

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of Artivion, Inc. (NYSE:AORT) by 30.2% in the second quarter, Holdings Channel.com reports. The institutional investor owned 63,405 shares of the company’s stock after selling 27,372 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Artivion were worth $1,425,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of AORT. Royal Bank of Canada lifted its stake in Artivion by 73.1% in the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after buying an additional 39,553 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Artivion during the 1st quarter worth approximately $5,530,000. Summit Creek Advisors LLC acquired a new stake in shares of Artivion during the 2nd quarter worth approximately $2,704,000. Fifth Third Bancorp grew its position in shares of Artivion by 58,029.7% during the 1st quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock worth $4,513,000 after buying an additional 123,023 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Artivion by 47.0% in the 1st quarter. Sei Investments Co. now owns 168,012 shares of the company’s stock valued at $6,153,000 after acquiring an additional 53,728 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AORT shares. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group lifted their price target on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a report on Monday, June 1st. Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Finally, Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Insider Buying and Selling at Artivion

In other news, SVP Jean F. Holloway sold 977 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 90,460 shares of company stock valued at $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Artivion Price Performance

Shares of NYSE:AORT opened at $25.13 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The stock’s 50 day moving average is $26.27 and its 200-day moving average is $28.78. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -358.92 and a beta of 1.25.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Sell-side analysts forecast that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Artivion Profile

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.